Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers.

HER2-low-expressing breast cancer can benefit from the HER2-targeted therapy. Prediction of HER2-low expression is crucial for appropriate management. MRI features offer a solution to this clinical issue.